En tiempo real
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
366,1 EUR | -0,57 % | -1,56 % | +6,58 % |
27/03 | Argenx Se avanza en el desarrollo clínico del efgartigimod en la enfermedad de Sjogren primaria | CI |
26/03 | ARGENX SE : Scotiabank se mantiene neutral. | ZM |
Resumen de negocios
Número de empleados: 1 148
Ventas por actividad
EUR en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Antibody-based Medicines
100,0
%
| 391 | 100,0 % | 1 134 | 100,0 % | +190,23 % |
Ventas por región
EUR en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
87,8
%
| 359 | 91,9 % | 996 | 87,8 % | +177,12 % |
EMEA
5,9
%
| - | - | 67 | 5,9 % | - |
Japan
4,6
%
| 15 | 3,8 % | 52 | 4,6 % | +248,00 % |
China
1,7
%
| 4 | 1,0 % | 19 | 1,7 % | +368,86 % |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Founder | 52 | 01/01/08 | |
Karl Gubitz
DFI | Director of Finance/CFO | 54 | 01/06/21 |
Filip Borgions
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/15 |
Karen Massey
COO | Chief Operating Officer | 45 | 13/03/23 |
Peter Ulrichts
CTO | Chief Tech/Sci/R&D Officer | 44 | 01/01/23 |
Luc Truyen
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/04/22 |
Beth Delgiacco
IRC | Investor Relations Contact | - | 01/01/18 |
General Counsel | 54 | 14/02/22 | |
Marc Schorpion
HRO | Human Resources Officer | 66 | 01/12/18 |
Arjen Lemmen
PRN | Corporate Officer/Principal | 39 | 01/01/16 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Director/Board Member | 71 | 26/04/17 | |
Joseph deBethizy
BRD | Director/Board Member | 74 | 13/05/15 |
Pamela Klein
BRD | Director/Board Member | 63 | 28/04/16 |
Chairman | 66 | 15/10/08 | |
Founder | 52 | 01/01/08 | |
James Daly
BRD | Director/Board Member | 63 | 08/05/18 |
Steve Krognes
BRD | Director/Board Member | 56 | 27/02/23 |
Camilla Sylvest
BRD | Director/Board Member | 52 | 08/09/22 |
Ana Cespedes
BRD | Director/Board Member | 51 | 12/12/22 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 59 302 232 | 59 229 732 ( 99,88 %) | 0 | 99,88 % |
Información de la empresa
Empresas del grupo
Nombre | Categoría y sector |
---|---|
arGEN-X BV
arGEN-X BV Pharmaceuticals: OtherHealth Technology Part of argenx SE, arGEN-X BVBA is a Belgian company that manufactures antibody-based medicines. The private company is based in Zwijnaarde, Belgium. |
Pharmaceuticals: Other
|
Sector
Ventas por región
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
+6,58 % | 23,48 mil M | |
+2,73 % | 108 mil M | |
+9,59 % | 103 mil M | |
-12,59 % | 21,93 mil M | |
-3,29 % | 19,68 mil M | |
-35,36 % | 18,37 mil M | |
-13,29 % | 16,33 mil M | |
+4,68 % | 13,72 mil M | |
+34,25 % | 12,15 mil M | |
-6,78 % | 10,2 mil M |
- Bolsa
- Acciones
- Acción argenx SE - Euronext Bruxelles
- Empresa argenx SE